Table 1 Baseline characteristics of the patients stratified by the TyG index tertiles
Variable | T1(n = 332) | T2 (n = 327) | T3 (n = 327) | P value |
|---|---|---|---|---|
GRACE variables | Â | Â | Â | Â |
Age, years | 68.10 ± 11.89 | 66.65 ± 10.95 | 65.07 ± 11.24 | 0.003 |
SBP, mmHg | 131.28 ± 19.81 | 133.17 ± 22.69 | 132.25 ± 21.66 | 0.525 |
 h, bpm | 76.15 ± 14.41 | 78.15 ± 14.95 | 78.66 ± 14.96 | 0.071 |
Serum creatinine, umol/L | 77.60 (65.55, 90.75) | 78.10 (66.80, 92.70) | 73.20 (61.10, 90.20) | 0.046 |
CHF, n (%) | 125 (37.7) | 128 (39.1) | 142 (43.4) | 0.292 |
Previous MI, n (%) | 15 (4.5) | 21 (6.4) | 17 (5.2) | 0.548 |
ST-segment depression, n (%) | 129 (38.9) | 124 (37.9) | 155 (47.4) | 0.025 |
Elevated cardiac enzymes/markers, n (%) | 210 (63.3) | 221 (67.6) | 232 (70.9) | 0.108 |
GRACE score | 110.61 ± 31.99 | 109.54 ± 29.91 | 109.30 ± 32.31 | 0.851 |
the TyG index | 8.28 ± 0.29 | 8.96 ± 1.73 | 9.79 ± 0.47 | <0.001 |
Female, n (%) | 72 (21.7) | 83 (25.4) | 124 (37.9) | <0.001 |
BMI, kg/m2 | 23.58 ± 2.89 | 24.61 ± 2.78 | 24.77 ± 2.78 | <0.001 |
Smoking, n (%) | 181 (54.5) | 187 (57.2) | 173 (52.9) | 0.539 |
Previous PCI, n (%) | 30 (9.0) | 29 (8.9) | 24 (7.3) | 0.689 |
COPD, n (%) | 22 (6.6) | 20 (6.1) | 13 (4.0) | 0.291 |
Hypertension, n (%) | 208 (62.7) | 217 (66.4) | 214 (65.4) | 0.582 |
Diabetes mellitus, n (%) | 49 (14.8) | 105 (32.1) | 189 (57.8) | <0.001 |
AF, n (%) | 27 (8.1) | 20 (6.1) | 19 (5.8) | 0.431 |
Previous Stroke, n (%) | 25 (7.5) | 27 (8.3) | 23 (7.0) | 0.839 |
Laboratory measurements | Â | Â | Â | Â |
cTnT, pg/mL | 28.29 (10.73, 968.00) | 30.10 (11.84, 652.60) | 59.25 (13.36, 1006.60) | 0.233 |
BNP, pg/mL | 109.85 (45.03, 301.08) | 103.50 (32.60, 287.30) | 111.60 (38.10, 324.00) | 0.337 |
FBG (mmol/L) | 5.39 ± 1.18 | 6.41 ± 1.82 | 9.19 ± 4.03 | <0.001 |
TG (mmol/L) | 0.97 ± 0.28 | 1.63 ± 0.44 | 2.96 ± 1.68 | <0.001 |
TC (mmol/L) | 4.07 ± 1.07 | 4.50 ± 1.24 | 4.85 ± 1.23 | <0.001 |
HDL-C (mmol/L) | 1.22 ± 0.33 | 1.14 ± 0.28 | 1.10 ± 0.27 | <0.001 |
LDL-C (mmol/L) | 2.47 ± 0.81 | 2.81 ± 0.92 | 3.22 ± 2.86 | <0.001 |
LVEF | 55.16 ± 8.81 | 55.33 ± 8.74 | 54.22 ± 9.28 | 0.231 |
Diagnosis, n (%) | Â | Â | Â | 0.262 |
UA | 165 (49.7) | 157 (48.0) | 143 (43.7) | Â |
NSTEMI | 62 (18.7) | 77 (23.5) | 82 (25.1) | Â |
STEMI | 105 (31.6) | 93 (28.4) | 102 (31.2) | Â |
Angiographic data | Â | Â | Â | Â |
MVD, n (%) | 202 (60.8) | 228 (69.7) | 239 (73.1) | 0.002 |
LM, n (%) | 11 (3.3) | 23 (7.0) | 20 (6.1) | 0.091 |
Calcified lesions, n (%) | 42 (12.7) | 44 (13.5) | 50 (15.3) | 0.603 |
Thrombosis, n (%) | 20 (60.0) | 28 (8.6) | 31 (9.5) | 0.238 |
Long lesion, n (%) | 131 (39.5) | 153 (46.8) | 170 (52.0) | 0.005 |
CTO, n (%) | 54 (16.3) | 82 (25.1) | 67 (20.5) | 0.020 |
Number of stents | 1.35 ± 0.77 | 1.47 ± 0.91 | 1.56 ± 0.94 | 0.008 |
Length of stents, mm | 35.12 ± 23.70 | 38.71 ± 27.56 | 41.51 ± 28.00 | 0.008 |
bSS | 11.00 (7.00, 18.00) | 14.00 (8.00, 21.00) | 14.50 (8.50, 20.50) | <0.001 |
rSS | 2.00 (0.00, 6.00) | 3.00 (0.00, 7.50) | 3 (0.00, 8.00) | 0.010 |
ICR, n (%) | 198 (59.6) | 220 (67.3) | 236 (72.2) | 0.003 |
Discharge medications | Â | Â | Â | Â |
Aspirin, n (%) | 322 (97.0) | 320 (97.9) | 319 (97.6) | 0.770 |
P2Y12 receptor inhibitor, n (%) | 328 (98.8) | 324 (99.1) | 322 (98.5) | 0.775 |
Statins, n (%) | 321 (96.7) | 319 (97.6) | 319 (97.6) | 0.733 |
β-blockers, n (%) | 218 (65.7) | 231 (70.6) | 238 (72.8) | 0.124 |
ACEI/ARB, n (%) | 132 (39.8) | 149 (45.6) | 135 (41.3) | 0.295 |
Diuretics, n (%) | 50 (15.1) | 50 (15.3) | 51 (15.6) | 0.982 |
Insulin, n (%) | 4 (1.2) | 20 (6.1) | 46 (14.1) | <0.001 |
Oral hypoglycemic agents, n (%) | 22 (6.6) | 77 (23.5) | 123 (37.6) | <0.001 |